Patent ID: 11939382
Assignee: MEDIMMUNE LIMITED
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  Y | IPC A  C

Claim 10:
11. The nucleic acid of claim 10, wherein the nucleic acid sequence comprises a sequence at least 95% identical to SEQ ID NO:21, wherein SEQ ID NO:21 encodes the heavy chain variable domain of the first binding domain that specifically binds to PD-1, a sequence at least 95% identical to SEQ ID NO:23, wherein SEQ ID NO:23 encodes the light chain variable domain of the first binding domain that specifically binds to PD-1, a sequence at least 95% identical to SEQ ID NO:25, wherein SEQ ID NO:25 encodes the heavy chain variable domain of the second binding domain that specifically binds to TIGIT, and a sequence at least 95% identical to SEQ ID NO:27, wherein SEQ ID NO:27 encodes the light chain variable domain of the second binding domain that specifically binds to TIGIT; or
wherein the nucleic acid sequence comprises a sequence at least 95% identical to SEQ ID NO:22, wherein SEQ ID NO:22 encodes the heavy chain of the first binding domain that specifically binds to PD-1, a sequence at least 95% identical to SEQ ID NO:24, wherein SEQ ID NO:24 encodes the light chain of the first binding domain that specifically binds to PD-1, a sequence at least 95% identical to SEQ ID NO:26, wherein SEQ ID NO:26 encodes the heavy chain of the second binding domain that specifically binds to TIGIT, and a sequence at least 95% identical to SEQ ID NO:28, wherein SEQ ID NO:28 encodes the light chain of the second binding domain that specifically binds to TIGIT.